0001562180-20-003223.txt : 20200430
0001562180-20-003223.hdr.sgml : 20200430
20200430164436
ACCESSION NUMBER: 0001562180-20-003223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200428
FILED AS OF DATE: 20200430
DATE AS OF CHANGE: 20200430
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kanes Stephen
CENTRAL INDEX KEY: 0001612859
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 20836293
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-04-28
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001612859
Kanes Stephen
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
Chief Medical Officer
Stock Option (Right to Buy)
39.87
2020-04-28
4
A
false
9450.00
0.00
A
2030-04-28
Common Stock
9450.00
9450.00
D
The securities awarded on April 28, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 25% of the shares of common stock underlying this stock option award will vest on April 28, 2021, and the remaining 75% of the shares of common stock underlying this stock option award will vest on April 28, 2022, subject, in each case, to the Reporting Person's continued employment with the Issuer on each of the applicable vesting dates.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Stephen Kanes
2020-04-30
EX-24
2
stephenkanespoa2019.txt
STEPHEN KANES POA 2019
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer),
Erin Lanciani (SVP, People and Organizational Strategy), and Jennifer
Fitzpatrick (Vice President, Corporate Counsel) for as long as they
remain employees of Sage Therapeutics, Inc., and Laurie Burlingame of
Goodwin Procter, each acting singly, or their successors in role, to
take the following actions, acting as my agent and attorney-in-fact,
with full power of substitution:
(1) to prepare and sign on my behalf any Form 3, Form 4 or
Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am an executive officer
or director of Sage Therapeutics, Inc., and shall not be affected by
my subsequent disability or incompetence. I may revoke this Power of
Attorney by written notice delivered, in person or by nationally
recognized courier, to the attention of the SVP, General Counsel of
Sage Therapeutics, Inc.
/s/ Stephen J. Kanes
___________________________________________________
(Signature of Executive Officer or Director)
Name: Stephen J. Kanes
Date: 1/15/2019